Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy B. Hayden sold 9,160 shares of Sight Sciences stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.17, for a total transaction of $38,197.20. Following the completion of the sale, the insider owned 266,321 shares in the company, valued at approximately $1,110,558.57. This trade represents a 3.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Sight Sciences Stock Performance
Shares of NASDAQ:SGHT traded up $0.08 during mid-day trading on Tuesday, reaching $3.55. 166,363 shares of the company traded hands, compared to its average volume of 212,899. The company's 50 day moving average price is $3.71 and its 200-day moving average price is $3.13. The firm has a market cap of $183.54 million, a PE ratio of -3.62 and a beta of 2.47. The company has a debt-to-equity ratio of 0.51, a current ratio of 10.47 and a quick ratio of 9.99. Sight Sciences, Inc. has a 52 week low of $2.03 and a 52 week high of $8.45.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. The firm had revenue of $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. On average, equities analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.
Institutional Trading of Sight Sciences
Several hedge funds and other institutional investors have recently bought and sold shares of SGHT. ProShare Advisors LLC purchased a new stake in Sight Sciences in the fourth quarter worth $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in Sight Sciences in the fourth quarter worth $40,000. WealthTrust Asset Management LLC purchased a new stake in Sight Sciences in the fourth quarter worth $48,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Sight Sciences in the fourth quarter worth $50,000. Finally, Wells Fargo & Company MN increased its stake in Sight Sciences by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock worth $60,000 after purchasing an additional 5,781 shares during the period. Hedge funds and other institutional investors own 55.51% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the stock. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Citigroup restated a "neutral" rating and set a $3.60 target price (up previously from $3.20) on shares of Sight Sciences in a report on Thursday, May 22nd. Lake Street Capital boosted their target price on shares of Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a report on Friday, May 9th. Piper Sandler restated a "neutral" rating and set a $4.00 target price (up previously from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Finally, Wall Street Zen upgraded shares of Sight Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, June 28th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $4.10.
Get Our Latest Stock Analysis on SGHT
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Recommended Stories
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
